Replies to post #298792 on Amarin Corp Plc (AMRN)

[north40000]

You know as well as I do that GILD placed Vascepa in two arms of an oncology clinical trial some months back. Oncology is the focus of today’s BusinessWire PR, replete with multimedia slides. The PR said, inter alia:

...”Additional ongoing studies[beside a Phase 3 trial already halted for efficacy of Trodelvy in metastatic triple negative breast cancer and an ongoing registrational trial in bladder cancer] are evaluating the potential of Trodelvy as a treatment for NSCLC and other solid tumor types...both as a monotherapy and in combination with other treatments...Gilead intends to initiate numerous additional mid-stage and late stage studies in the near term to determine which patients will benefit from Trodelvy as both a monotherapy or in combination with other products.....”